An analysis of drugs known to exhibit potency in MSI-High Mut p53 cell lines revealed that most drugs inhibit kinases belonging to pathways known to be aberrant in MSI cancer cells (e.g., MAPK, ERK, PI3K, TGFB, WNT, and mTOR signaling pathways (Figure 4)), while RIOK1-specific inhibition is novel. Here, RIOK1 is linked to cancer.